Skip to main content
Account

Peer review reports

From: MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib

Original Submission
11 Jan 2023 Submitted Original manuscript
1 Apr 2023 Reviewed Reviewer Report
20 Jun 2023 Reviewed Reviewer Report
10 Jul 2023 Author responded Author comments - jie zhao
Resubmission - Version 2
10 Jul 2023 Submitted Manuscript version 2
8 Aug 2023 Author responded Author comments - jie zhao
Resubmission - Version 3
8 Aug 2023 Submitted Manuscript version 3
9 Aug 2023 Author responded Author comments - jie zhao
Resubmission - Version 4
9 Aug 2023 Submitted Manuscript version 4
12 Aug 2023 Author responded Author comments - jie zhao
Resubmission - Version 5
12 Aug 2023 Submitted Manuscript version 5
Publishing
19 Aug 2023 Editorially accepted
12 Oct 2023 Article published 10.1186/s12885-023-11320-4

Learn about peer review

Back to article page

Navigation